Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosed with T2DM duration of T2DM \> 2 years~2. Insulin naïve~3. Continuous treatment with stable doses of 2 OADs (sulphonylureas, biguanides, alpha-glucosidase inhibitors, DPP-IV inhibitors, and glinides) for \> three months prior to randomization~4. HbA1c levels 7% and 11 %~5. Body mass index (BMI) 20 and 40 kg/m2~6. Willing and able to perform blood glucose monitoring using a blood glucose meter~Exclusion criteria:~1. Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agent intake),~2. Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for \< 1 week),~3. Current treatment with thiazolidinediones,~4. Current or previous use (within the last 3 months) of GLP-1 receptor agonists or GLP-1 analogues,~5. Current or previous (within the last 3 months) use of any treatment for weight lost,~6. Active proliferative diabetic retinopathy,~7. Patient without any history of eye examination in the past 6 months,~8. Treatment with systemic corticosteroids in the 3 months prior to study entry,~9. Currently receiving treatment with monoamine oxidase inhibitors,~10. Currently receiving treatment with non-selective -blockers,~11. Treatment with any investigational product and/or device in the 2 months prior to study entry,~12. Likelihood of requiring treatment during the study period with drugs not permitted by the clinical trial protocol,~13. History of ketoacidosis or hyperosmolar hyperglycemic state,~14. History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months,~15. History of congestive heart failure,~16. History of hypoglycemia unawareness,~17. Unexplained hypoglycemia in the past 6 months,~18. Impaired renal function defined as, but not limited to, serum creatinine 1.5 mg/dL (133 mol/L) males or 1.4 mg/dL (124 mol/L) females or presence of macroproteinuria (\>2gr/day),~19. Active liver disease (alanine transaminase ALAT greater than two times the upper limit of the reference range, as defined by the local laboratory),~20. Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol,~21. Had a blood transfusion or severe blood loss within the 3 months before screening, or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia,~22. Known hypersensitivity / intolerance to insulin glargine or any of its excipients,~23. History of pancreatitis,~24. Currently undergoing therapy or planned radiological examinations requiring the administration of contrasting agents for malignancy (other than non-metastatic / early stage basal cell or squamous cell carcinoma),~25. Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method),~26. Any medical condition that may have an influence on HbA1c rate.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
- Usual standard of care group (Type: ACTIVE_COMPARATOR): Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician

Based on this trial design, predict the completion outcome and termination type (if applicable).